CoChat

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

Open access
Chen, Jinxia, Xu, Zhiyuan, Hu, Can, Zhang, Shengjie, Zi, Mengli, Yuan, Li, Cheng, Xiangdong · 2023 · Frontiers in Oncology

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Abstract

Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18.2(CLDN18.2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function. Its characteristic widespread expression in tumour tissues and its exposed extracellular loops make it an ideal target for researchers to develop targeted strategies and immunotherapies for cancers of the GI tract. In the present review, we focus on the expression pattern of CLDN18.2 and its clinical significance in GI cancer. We also discuss the tumour-promoting and/or tumour-inhibiting functions of CLDN18.2, the mechanisms regulating its expression, and the current progress regarding the development of drugs targeting CLDN18.2 in clinical research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2023.1132319

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic structure of CLDN18 protein.
Figure 1 Schematic structure of CLDN18 protein.CC BY · PubMed Central
Figure 2 Methylation status of CpG islands and CLDN18 gene expression. (A) Unmethylated CpG island and expressed CLDN18.2 gene. (B) Methylation of CpG islands blocks the binding of transcription factors to the CLDN18.2 promoter, resulting in CLDN18.2 gene silencing.
Figure 2 Methylation status of CpG islands and CLDN18 gene expression. (A) Unmethylated CpG island and expressed CLDN18.2 gene. (B) Methylation of CpG islands blocks the binding of transcription factors to the CLDN18.2 promoter, resulting in CLDN18.2 gene silencing.CC BY · PubMed Central
Figure 3 The PKC pathway and ERK/MAPK pathway regulate CLDN18.2 expression. AP-1 could bind to cis-regulatory elements (CREs) of the CLDN18.2 promoter, increasing the transcriptional activity of CLDN18.2. The PKC and ERK-MAPK pathways enhance the transcription of CLDN18.2 mRNA by stimulating the phosphorylation and activation of AP-1.
Figure 3 The PKC pathway and ERK/MAPK pathway regulate CLDN18.2 expression. AP-1 could bind to cis-regulatory elements (CREs) of the CLDN18.2 promoter, increasing the transcriptional activity of CLDN18.2. The PKC and ERK-MAPK pathways enhance the transcription of CLDN18.2 mRNA by stimulating the phosphorylation and activation of AP-1.CC BY · PubMed Central
Figure 4 Activation of the HER2/HER3 signalling pathway and its effect after activation. The PI3K-AKT and MAPK signalling pathways are the two main signal transduction pathways downstream of HER2/3 heterodimerisation activation and are involved in cell growth, cell proliferation, the cell cycle, protein synthesis and so on. In addition, the HER2/HER3 signalling pathway regulates barrier function by regulating the expression of CLDN18, but the mechanism is unclear.
Figure 4 Activation of the HER2/HER3 signalling pathway and its effect after activation. The PI3K-AKT and MAPK signalling pathways are the two main signal transduction pathways downstream of HER2/3 heterodimerisation activation and are involved in cell growth, cell proliferation, the cell cycle, protein synthesis and so on. In addition, the HER2/HER3 signalling pathway regulates barrier function by regulating the expression of CLDN18, but the mechanism is unclear.CC BY · PubMed Central
Figure 5 MiRNAs regulate the expression of CLDN18. MiRNAs bind with 3’-UTR of CLDN18 mRNA, resulting in the degradation of mRNA or the inhibition of translation.
Figure 5 MiRNAs regulate the expression of CLDN18. MiRNAs bind with 3’-UTR of CLDN18 mRNA, resulting in the degradation of mRNA or the inhibition of translation.CC BY · PubMed Central
Figure 6 Mechanisms of CLDN18.2-targeted monoclonal antibody intervention and CAR T cell interaction. Monoclonal antibody could specifically bind to CLDN18.2 expressed tumour cells and induce ADCC and CDC, resulting in the cell lysis. CLDN18.2 CAR T cell could also specifically recognise CLDN18.2 expressed tumour cells and induce cytokine release, resulting in the cell lysis.
Figure 6 Mechanisms of CLDN18.2-targeted monoclonal antibody intervention and CAR T cell interaction. Monoclonal antibody could specifically bind to CLDN18.2 expressed tumour cells and induce ADCC and CDC, resulting in the cell lysis. CLDN18.2 CAR T cell could also specifically recognise CLDN18.2 expressed tumour cells and induce cytokine release, resulting in the cell lysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 79

Metadata

Authors
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X.
Affiliations
Zhejiang Cancer Hospital (CN)
Corresponding author
Cheng, Xiangdong
Venue
Frontiers in Oncology
Published
2023-03-10
Volume
13
Pages
1132319-1132319
ISSN
2234-943X (ISSN-L)
OpenAlex
W4323860370
Cited by
78
References
102
Citations by year
2026: 20 · 2025: 22 · 2024: 32 · 2023: 4
FWCI
3.63
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82074245, 81973634)
  • Natural Science Foundation of Zhejiang Province (HDMY22H160008)
  • Medical Science and Technology Project of Zhejiang Province (2022KY114, WKJ-ZJ-2104)
  • Postdoctoral Research Foundation of China (2022M713203)
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
claudin 18.2, gastrointestinal cancer, targeted therapy, immunotherapy, tight junctions, drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.